Anatara Lifesciences is developing non-antibiotic oral solutions for gastrointestinal diseases in animals and humans. Our lead product Detach is a natural product that has been shown to aid in the control of scour in piglets. Anatara has signed an exclusive licensing agreement with Zoetis Inc., the leading global animal health company, for the worldwide development, manufacture, distribution and marketing of Detach. The Anatara team has a strong track record in biological science as well as building and growing international biotech companies.
Latest news All news
PAC Partners Research has released its latest research and valuation report on Anatara Lifesciences (ANR). The report maintained a BUY rating and a price target of $1.40 per share.
“Restore human gut health with GaRP”
Please open the attached PDF to view the report.
Anatara Lifesciences is pleased to release its Appendix 4C Quarterly Financial Report for the quarter ended 30 June 2018.
Please click here to view the ASX announcement.